Sanjay Chanda
Corporate Officer/Principal bei AN2 THERAPEUTICS, INC.
Vermögen: 64 376 $ am 30.04.2024
Profil
Sanjay Chanda is the founder of Auration Biotech, Inc. founded in 2014.
He is currently the Chief Development Officer at AN2 Therapeutics, Inc. since 2019 and at Cortene, Inc. since 2017.
Dr. Chanda's former jobs include Senior Vice President-Drug Development at Anacor Pharmaceuticals LLC from 2013 to 2016 and Chief Development Officer at Arch Oncology, Inc. from 2016 to 2017.
Dr. Chanda's education history includes undergraduate and graduate degrees from Birla Institute of Technology & Science and a doctorate from Northeast Louisiana University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
AN2 THERAPEUTICS, INC.
0,09% | 15.03.2024 | 28 235 ( 0,09% ) | 64 376 $ | 30.04.2024 |
Aktive Positionen von Sanjay Chanda
| Unternehmen | Position | Beginn |
|---|---|---|
| AN2 THERAPEUTICS, INC. | Corporate Officer/Principal | 01.11.2019 |
Cortene, Inc.
 Cortene, Inc. BiotechnologyHealth Technology Cortene, Inc. develops interventional treatment for myalgic encephalomyelitis. The company is headquartered in Burlingame, CA. | Corporate Officer/Principal | 01.02.2017 |
Ehemalige bekannte Positionen von Sanjay Chanda
| Unternehmen | Position | Ende |
|---|---|---|
Arch Oncology, Inc.
 Arch Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA. | Corporate Officer/Principal | 01.08.2017 |
| ANACOR PHARMACEUTICALS INC | Corporate Officer/Principal | 01.10.2016 |
Auration Biotech, Inc.
 Auration Biotech, Inc. Miscellaneous Commercial ServicesCommercial Services Auration Biotech, Inc. develops novel therapeutics for the treatment of diseases of the ear, nose, and throat. The private company is based in Dover, DE. The company was founded by Sanjay Chanda. Benjamin F. McGraw has been the CEO of the company since 2014. | Gründer | - |
Ausbildung von Sanjay Chanda
| Birla Institute of Technology & Science | Graduate Degree |
| Northeast Louisiana University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| AN2 THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Anacor Pharmaceuticals LLC
 Anacor Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Anacor Pharmaceuticals, Inc. develops medical solutions. The firm operates as a biopharmaceutical company, which focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company was founded by Lucy Shapiro, Stephen J. Benkovic, and David P. Perry in 2000 and is headquartered in Palo Alto, CA. | Health Technology |
Arch Oncology, Inc.
Arch Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA. | Commercial Services |
Auration Biotech, Inc.
Auration Biotech, Inc. Miscellaneous Commercial ServicesCommercial Services Auration Biotech, Inc. develops novel therapeutics for the treatment of diseases of the ear, nose, and throat. The private company is based in Dover, DE. The company was founded by Sanjay Chanda. Benjamin F. McGraw has been the CEO of the company since 2014. | Commercial Services |
Cortene, Inc.
Cortene, Inc. BiotechnologyHealth Technology Cortene, Inc. develops interventional treatment for myalgic encephalomyelitis. The company is headquartered in Burlingame, CA. | Health Technology |
